LOGO - Color (1).jpg
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
10 mars 2025 08h00 HE | PMGC Holdings Inc.
Northstrive Biosciences, Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination
LOGO - Color (1).jpg
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
04 févr. 2025 08h00 HE | PMGC Holdings Inc.
Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio
LOGO - Color (1).jpg
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
30 janv. 2025 08h00 HE | PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Th
LOGO - Color (1).jpg
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
24 janv. 2025 08h00 HE | PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
09 déc. 2024 08h00 HE | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscl
800 px horizontal logo.png
CORRECTION - Elevai Labs Inc.
14 nov. 2024 14h35 HE | Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
800 px horizontal logo.png
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
14 nov. 2024 09h08 HE | Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
22 oct. 2024 09h54 HE | Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
21 oct. 2024 07h30 HE | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl